CD­MO makes an AI and drug dis­cov­ery play in lat­est, small-time ac­qui­si­tion

The CD­MO out­fit iBio has net­ted a deal that sees it gain ac­cess to an AI-based plat­form as well as new ther­a­peu­tic can­di­dates as it looks to dive fur­ther in­to drug dis­cov­ery.

iBio closed on ac­quir­ing sev­er­al as­sets from the San Diego-based biotech RubrYc Ther­a­peu­tics, snap­ping up sev­er­al on­col­o­gy pro­grams. The cost in­cludes a $1 mil­lion up­front pay­ment as well as the abil­i­ty of RubrYc’s in­vestors to re­ceive up to $5 mil­lion in mile­stones over the next sev­er­al years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER